Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Blis MD vs myRocky

Blis MD
Graded #74

Higher grade

vs+21.300000000000004
myRocky
Graded #487

Lower grade

The verdict

Blis MD takes it — 72.7/100 to 51.4/100.

Blis MD grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Blis MD is a US telehealth offering personalized GLP-1 weight-loss treatment with compounded semaglutide and tirzepatide, prescribed after a free virtual consultation with a licensed provider.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueBlis MD +54
88
34
Dose & formulationBlis MD +19
72
53
Clinical oversightBlis MD +10
74
64
Labs & monitoringBlis MD +10
62
52
FulfillmentmyRocky +5
65
70
Contract termsBlis MD +14
55
41
Blis MD · left barmyRocky · right bar

The numbers

MetricBlis MDmyRocky
WeighScore72.7/10051.4/100
GradeCC
Scorecard rank#74#487
Semaglutide$139/moNot disclosed
Tirzepatide$199/moNot disclosed
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyInjection only
Blis MD

Graded #74 · C

Strengths

  • Transparent flat monthly pricing published upfront (139 dollars semaglutide, 199 dollars tirzepatide)
  • Free initial virtual consultation with a licensed provider
  • Both semaglutide and tirzepatide offered with ongoing provider check-ins

Where it loses points

  • Compounding pharmacy is not named publicly
  • States served are not listed on the site
  • Thin public trust signals (no LegitScript seal or named medical director found)
myRocky

Graded #487 · C

Strengths

  • Brand-name FDA-approved GLP-1s (Ozempic, Mounjaro, Wegovy) on one platform — no compounded-product risk
  • LegitScript Approved
  • 42-state coverage with an 8-state expansion roadmap published
  • Multi-product platform for patients managing GLP-1 plus sexual health, hair loss, or mental health on one subscription

Where it loses points

  • Expensive stacked fees: $99 consult + $99/mo program fee + ~$1,409/mo medication = ~$1,508/mo
  • Canadian incorporation (Rocky Health Inc., Mississauga, ON) — verify your state's prescriber holds an active US license
  • Listed pharmacy is a Canadian community pharmacy; US-fulfillment supply chain not transparent
  • Brand-only — no compounded option for cost-sensitive patients
  • $1,409/mo Ozempic is near retail; compare NovoCare ($349/mo Wegovy pen) or LillyDirect ($449–$699/mo Zepbound)

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard